{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:08:00Z","timestamp":1790712480928,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jid.2025.06.1598","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:11:11Z","timestamp":1755252671000},"page":"669-677.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-8547","authenticated-orcid":false,"given":"Sandra","family":"Garcet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-5722","authenticated-orcid":false,"given":"Lam C.","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-9188","authenticated-orcid":false,"given":"Hong","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-6519","authenticated-orcid":false,"given":"Bruce","family":"Konicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-860X","authenticated-orcid":false,"given":"Zhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0162-4109","authenticated-orcid":false,"given":"Richard E.","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6976-5138","authenticated-orcid":false,"given":"Ernst R.","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2455-1467","authenticated-orcid":false,"given":"David C.","family":"Gemperline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7354-7402","authenticated-orcid":false,"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3552-9345","authenticated-orcid":false,"given":"Hany","family":"Elmaraghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3449-3021","authenticated-orcid":false,"given":"Brian J.","family":"Nickoloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-6598","authenticated-orcid":false,"given":"Venkatesh","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-1778","authenticated-orcid":false,"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-0812","authenticated-orcid":false,"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.06.1598_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.06.1598_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.06.1598_bib3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.06.1598_bib4","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.06.1598_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","article-title":"Patient-relevant treatment goals in psoriasis","volume":"308","author":"Blome","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2025.06.1598_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/09546634.2016.1230174","article-title":"Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians","volume":"28","author":"Carrascosa","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.06.1598_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13555-019-00334-1","article-title":"Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey","volume":"9","author":"Gorelick","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.06.1598_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-018-03704-z","article-title":"Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2025.06.1598_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl9165","article-title":"Classification of human chronic inflammatory skin disease based on single-cell immune profiling","volume":"7","author":"Liu","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib13","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2025.06.1598_bib14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice","volume":"33","author":"Maul","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.06.1598_bib15","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved psoriasis lesions retain expression of a subset of disease-related genes","volume":"131","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.06.1598_bib17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13555-019-00337-y","article-title":"Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using bayesian and frequentist network meta-analyses","volume":"10","author":"Warren","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.06.1598_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi2848","article-title":"A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response","volume":"9","author":"Wu","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jid.2025.06.1598_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","article-title":"Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year","volume":"33","author":"Yasmeen","year":"2022","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25023413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25023413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:28:09Z","timestamp":1779942489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25023413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022202X25023413"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.06.1598","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.06.1598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}